Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness-Reference-Cited by-同舟云学术

Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness

Published:2022-04-15 Issue:4 Volume:14 Page:920-934
ISSN:1948-5204
Container-title:World Journal of Gastrointestinal Oncology
language:
Short-container-title:WJGO

Author:

Xu Yu-Jie,Zhang Peng,Hu Jin-Long,Liang Hong,Zhu Yan-Yan,Cui Yao,Niu Po,Xu Min,Liu Ming-Yue

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,Oncology

Reference36 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. Cancer statistics in China, 2015

4. Correction: Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer

5. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis;Clinical and Experimental Medicine;2024-07-03

2. Regorafenib in patients with pretreated advanced melanoma: a single-center case series;Melanoma Research;2024-05-27

3. Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis;Oncology Letters;2024-02-14

4. RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab;Oncology;2023-12-07

5. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients;BMC Immunology;2023-09-01